Literature DB >> 2702571

Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.

J V Teichmann1, G Sieber, W D Ludwig, H Ruehl.   

Abstract

Interferons (IFN) are known to modulate immune responses in an either stimulatory or inhibitory manner. Most of the knowledge about immunomodulatory activities of IFN comes from investigations of IFN effects on cells in vitro. This study examines the influence which long-term treatment with recombinant interferon-alpha 2 exerts on immune functions in cancer patients. Serial in vitro immune function studies of peripheral blood mononuclear cells were done to determine parameters of B-cell and T-cell functions as well as natural killer (NK)-cell activity. The authors detected profound suppression of in vitro immunoglobulin synthesis and lymphocyte proliferation as well as depression of NK-cell activity during IFN treatment. All suppressed immune functions normalized on discontinuation of IFN therapy. The authors conclude from these observations that, apart from their beneficial effects, IFN produce substantial immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702571     DOI: 10.1002/1097-0142(19890515)63:10<1990::aid-cncr2820631020>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Potential uses of interferon alpha 2 as adjuvant therapy in cancer.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

2.  Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations.

Authors:  A J Beniers; R J van Moorselaar; W P Peelen; F M Debruyne; J A Schalken
Journal:  Urol Res       Date:  1991

3.  Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon alpha.

Authors:  W M Vuist; M J Visseren; M Otsen; K Bos; F A Vyth-Dreese; C G Figdor; C J Melief; A Hekman
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

Review 4.  Clinical toxicity of the interferons.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606

Review 5.  The role of interferons in the treatment of malignant neoplasms.

Authors:  J R Murren; A C Buzaid
Journal:  Yale J Biol Med       Date:  1989 May-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.